S. Soleymani

发表

PYGO2 as an independent diagnostic marker expressed in a majority of colorectal cancers

A. Jafarian, M. Forghanifard, Sima Ardalan Khales, 2019, Journal of histotechnology.

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

J. Ajani, T. Zander, A. Lièvre, 2021, Annals of Oncology.

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

A. El-Khoueiry, J. Neely, F. Tovoli, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.

A. El-Khoueiry, S. Choo, J. Neely, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.